SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Samrat Pharma reports net loss of Rs 1.63 crore in Q4

01 Jun 2012 Evaluate

Samrat Pharma has reported results for fourth quarter and year ended March 31, 2012.

The company has reported net loss of Rs 1.63 crore for the quarter ended March 31, 2012, against net  profit of Rs 0.35 crore for the corresponding period last fiscal. However, total income increased by 46.94% at Rs 15.59 crore during the quarter under review from Rs 10.61 crore in the year-ago period.

For the full year ended March 31, 2012, the company has posted a rise of 181.34% in its net profit at Rs 3.77 crore as compared to Rs 1.34 crore for the same period in the previous year. Total income has increased by 60.14% at Rs 69.55 crore for year under review as compared to Rs 43.43 crore for the period ended March 31, 2011.

Samrat Pharmachem Share Price

221.15 0.00 (0.00%)
22-Apr-2026 10:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.40
Dr. Reddys Lab 1215.55
Cipla 1228.55
Zydus Lifesciences 926.50
Lupin 2307.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×